title: Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy.
abstract: OBJECTIVE
  Symptom control does not reflect elimination of abnormal acid reflux or abnormal bile reflux in patients with long-segment Barrett esophagus receiving proton pump inhibitors (PPIs).
  
  
  METHODS
  Prospective survey.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  Thirty-two patients with long-segment Barrett esophagus who were asymptomatic with PPIs.
  
  
  METHODS
  Twenty-four-hour ambulatory pH and bile reflux monitoring while continuing PPIs.
  
  
  RESULTS
  Abnormal acid reflux (pH <4 for 11.9% [interquartile range, 6.8%-19.6%) of 24 hours] persisted in 15 patients (47%) who could not be distinguished from those with normal acid reflux (pH <4 for <4.5% of 24 hours) by any endoscopic, manometric, or therapeutic characteristic. Abnormal bile reflux (absorbance >0.14 for 8.7% [interquartile range, 3.9%-8.7%] of 24 hours) was detected in 11 (48%) of 23 patients, such that both normal bile reflux (absorbance >0.14 for <1.8% of 24 hours) and normal acid reflux were observed in only 8 patients (35%). There was no association between abnormal acid reflux and abnormal bile reflux.
  
  
  CONCLUSIONS
  Despite symptom control with PPIs, both acid reflux and bile reflux were controlled in only one third of patients. Posttherapeutic monitoring of acid and bile reflux is recommended in future clinical trials of PPI treatment vs laparoscopic antireflux surgery.
authors.affiliation: Academic Unit of Surgery, School of Medicine, University of Leeds, and Department of General Surgery, St Jame's University Hospital, Leeds, England, UK. asarela@leeds.ac.uk
authors.forename: Abeezar I
authors.initials: AI
authors.lastname: Sarela
authors.forename: David G
authors.initials: DG
authors.lastname: Hick
authors.forename: Caroline S
authors.initials: CS
authors.lastname: Verbeke
authors.forename: John F
authors.initials: JF
authors.lastname: Casey
authors.forename: Pierre J
authors.initials: PJ
authors.lastname: Guillou
authors.forename: Geoffrey W B
authors.initials: GW
authors.lastname: Clark
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001471:Barrett Esophagus / Q000150:complications* / Q000188:drug therapy*; D001562:Benzimidazoles / Q000627:therapeutic use; D004945:Esophagoscopy; D004947:Esophagus / Q000503:physiopathology; D005260:Female; D005764:Gastroesophageal Reflux / Q000209:etiology*; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008365:Manometry; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D054328:Proton Pump Inhibitors; D064750:Rabeprazole
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D064750:Rabeprazole; D009853:Omeprazole